Recent Pfizer Press Releases

  • 2/19/19 9:32 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the European Commission (EC) has approved ZIRABEV™ for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix.1,2 “Pfizer is dedicated to increasing accessmore...
  • 2/11/19 5:00 pm EST

    Data to be presented at the 2019 Genitourinary Cancers Symposium

    NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today results from the Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC). Prostate cancer is considered metastatic once the cancer has spread outside of the prostate gland to other parts of the body.1 Men are considered hormone (or castration) sensitive ifmore...
  • 2/1/19 9:17 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vizimpro® (dacomitinib) 45 mg, as monotherapy, be granted marketing authorization in the European Union (EU) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factormore...
  • 1/29/19 6:45 am EST

    PROVIDES 2019 FINANCIAL GUIDANCE

    • Full-Year 2018 Revenues of $53.6 Billion, Reflecting 2% Operational Growth; Fourth-Quarter 2018 Revenues of $14.0 Billion, Reflecting 5% Operational Growth
    • Full-Year 2018 Reported Diluted EPS(1) of $1.87, Adjusted Diluted EPS(2) of $3.00; Fourth-Quarter 2018 Reported Loss Per Share(1) of $0.07, Adjusted Diluted EPS(2) of $0.64
    • Returned $20.2 Billion Directly to Shareholders in 2018 Through Share Repurchases and Dividends; Anticipates Repurchasing Approximately $9 Billion of Shares in 2019
    • Provides 2019 Financial Guidance
      • Reflects a Full Year of Revenue and Expense Contributions from Consumer Healthcare(3)
      • Reflects Anticipated Unfavorable Impact of Foreign Exchange of Approximately $0.9 billion on Revenues and Approximately $0.06 on Adjusted Diluted EPS(2)
      • Guidance for Adjusted Diluted EPS(2) Excludes the Impact of Gains and Losses on Equity Investments, Which Favorably Impacted 2018 Adjusted Diluted EPS(2) by $0.08
      • Revenue Guidance of $52.0 to $54.0 Billion and Adjusted Diluted EPS(2) Guidance of $2.82 to $2.92; Midpoints of These Ranges Imply Essentially Flat Operational Performance Compared to 2018 Excluding the Unfavorable Impact of Foreign Exchange and Net Gains on Equity Investments from 2018 Results
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2018 and provided 2019 financial guidance. Results for the fourth quarter and the full year of 2018 and 2017(4) are summarized below. OVERALL RESULTSmore...
  • 1/29/19 6:30 am EST
    NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain. The tanezumab 5 mg treatment arm met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients’ overallmore...
  • 1/14/19 8:00 am EST

    —FDA grants a Priority Review based on Phase 3 ATTR-ACT study findings in ATTR-CM—

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company’s New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete a Phase 3 trial evaluating its efficacy, safety, andmore...
  • 1/3/19 8:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body, and currently has no approved therapies.1,2 “We are proud to start this global pivotal Phase 2b/3 trial for PF-06651600 in patients withmore...
  • 12/31/18 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8:30 a.m. Pacific Standard Time. Effective January 1, 2019, Albert Bourla will become Chief Executive Officer. To listen to themore...
  • 12/27/18 10:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, at the Goldman Sachs 11th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 3, 2019 at 10:15 a.m. Eastern Standard Time. Effective January 1, 2019, Albert Bourla will become Chief Executive Officer. To listen to the webcast, visit our web site at www.pfizermore...
  • 12/20/18 4:30 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the Phase 2b trial STRIVE (STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy) evaluating the company’s investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) is being discontinued due to futility. This decision is based on a recommendation from an independent Data Monitoring Committee (DMC), composed of external experts, after conducting a pre-more...